L-Theanine adjunct to risperidone in the treatment of chronic schizophrenia inpatients: a randomized, double-blind, placebo-controlled clinical trial
ConclusionsL-Theanine adjunct to risperidone safely and tolerably outperformed adjunctive placebo for schizophrenia, and promising evidence indicated its effects on primary negative symptoms, which need to be scrutinized in further studies.Trial registrationThe study protocol was registered and published prospectively in the Iranian Registry of Clinical Trials (http://www.irct.ir; registration number: IRCT20090117001556N133) on 2020 –12-12.
Source: Psychopharmacology - Category: Psychiatry Source Type: research
More News: Brain | Clinical Trials | Depression | Iran Health | Neurology | Psychiatry | Risperdal Consta | Schizophrenia | Study